Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
11 Julho 2023 - 9:30AM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, today announced the appointment of
Brant Binder and Richard Wagner, Ph.D. to its Board of Directors.
Concurrently, Charles Cherington and Nicholas Singer have stepped
down from the Board.
“We are delighted to welcome Brant and Richard to our Board.
Both bring a wealth of industry expertise, including founding and
leading biotechnology companies with a proven history of delivering
value for their stakeholders,” said Matt Angel, Ph.D., Chief
Executive Officer and President of Eterna. “We look forward to
working together to drive Eterna’s future growth.”
Brant Binder is a seasoned leader and
entrepreneur with more than 25 years of strategic expertise
building and growing biotechnology companies. Mr. Binder began his
career in venture capital and private equity investment at Trust
Company of the West. He received a B.S.F.S. in International
Relations from the School of Foreign Service at Georgetown
University and an MBA from the Sloan School of Management at the
Massachusetts Institute of Technology.
Richard Wagner, Ph.D., is a biotechnology
entrepreneur with more than 30 years of experience creating and
managing drug discovery innovations. He is an expert in the
invention and industrialization of novel technologies to accelerate
the discovery of small molecule and biologic therapeutic products.
Dr. Wagner received a B.S. in biochemistry from Trinity College and
a Ph.D. in chemistry from Brown University.
Since 2007, Mr. Binder and Dr. Wagner have worked together to
exploit innovations in the biotechnology field. They recently
co-founded and operate Bonito Biosciences, an oligonucleotide
therapeutics company. Prior to this, they co-founded ZebiAI
Therapeutics, alongside Google, to pioneer the use of machine
learning in drug discovery; they sold ZebiAI to Relay Therapeutics,
Inc. in 2021. Earlier, they launched X-BODY Biosciences, which
developed antibody and T-cell receptor domains for CAR-T
applications, and was acquired by Juno Therapeutics. Additionally,
they launched X-Chem, Inc., applying DNA encoded libraries of small
molecules, which resulted in more than 70 drug discovery programs
being licensed to pharma and biotech partners, six spin-out
companies, and technology transfer of the platform into major
pharma and biotech organizations. X-Chem was acquired twice, once
by PPD, Inc. in 2014, and later by GHO Capital in 2020. Both Mr.
Binder and Dr. Wagner served in executive operating roles and on
the Board of Directors of the foregoing companies.
Mr. Binder commented, “I am eager to contribute to Eterna's
momentum as the Company makes progress supporting the development
of next-generation mRNA-based therapeutic products. I look forward
to bringing my experience working with growth-stage biotechnology
companies as Eterna continues to advance its corporate
strategy.”
Dr. Wagner commented, “This is an exciting time to join the
Eterna Board following its recent scientific and business
achievements. I look forward to working with my fellow Board
members and the entire team at Eterna as the Company continues to
explore strategic partnerships to expand the reach of its
technology.”
Matt Angel added, “On behalf of the entire Board of Directors, I
would also like to thank Charles and Nicholas for their dedication
to Eterna during what has been a monumental year for the Company,
including the Company entering into its first income-generating
strategic partnership and its recent acquisition of Exacis
Biotherapeutics.”
Mr. Singer, who is the Founder and Managing Partner of
investment firm Purchase Capital, added, “It has been a privilege
to be a part of Eterna’s exciting growth story. I am confident in
the team’s continued success and ability to herald transformational
new medicines by harnessing its mRNA-based technology portfolio and
leveraging existing and future partnerships.”
Mr. Cherington, who is Managing Partner at Ara Partners,
commented, “It has been my sincere honor to work alongside this
established team as Eterna’s Chairman of its Board of Directors. I
am incredibly proud of Eterna’s many achievements and the work
management has done to position the Company for long-term
success.”
About Eterna TherapeuticsEterna Therapeutics is
a life science company committed to realizing the potential of mRNA
cell engineering to provide patients with transformational new
medicines. Eterna has in-licensed a portfolio of over 130 patents
covering key mRNA cell engineering technologies, including
technologies for mRNA cell reprogramming, mRNA gene editing, the
NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™
mRNA delivery system from Factor Bioscience. NoveSlice™,
UltraSlice™, and ToRNAdo™ are trademarks of Factor Bioscience. For
more information, please visit www.eternatx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Eterna’s business model into a platform company
focused on mRNA, iPS cell and gene editing technologies; (ii)
Eterna’s ability to successfully, cost-effectively and efficiently
develop its technology and products; (iii) Eterna’s ability to
successfully commence clinical trials of any products on a timely
basis or at all; (iv) Eterna’s ability to successfully fund and
manage the growth of its development activities; and (v) Eterna ’s
ability to obtain regulatory approvals of its products for
commercialization. You should not rely upon forward-looking
statements as predictions of future events. The forward-looking
statements made in this communication speak only as of the date on
which they were made, and Eterna does not undertake any obligation
to update the forward-looking statements contained herein to
reflect events that occur or circumstances that exist after the
date hereof, except as required by applicable law. Factors that may
cause Eterna’s actual results to differ from those expressed or
implied in forward-looking statements contained in this press
release are more fully disclosed in Eterna’s periodic public
filings with the U.S. Securities and Exchange Commission,
particularly under the heading “Risk Factors” in Eterna’s Annual
Report on Form 10-K for the year ended December 31, 2022, as well
as under similar headings in Eterna’s subsequently filed Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K.
Eterna Therapeutics
Investorsinvestors@eternatx.com
Eterna Therapeutics
MediaEternaPR@westwicke.com
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024